UNITED STATES
                       SECURITIES AND EXCHANGE COMMISSION
                              Washington, DC 20549


                                    FORM 8-K

                                 CURRENT REPORT
                     Pursuant to Section 13 or 15(d) of the
                         Securities Exchange Act of 1934

       Date of Report (Date of earliest event reported): November 2, 2017

                               CEL-SCI CORPORATION
                 -----------------------------------------------
             (Exact name of registrant as specified in its charter)

          Colorado                       001-11889               84-0916344
 -------------------------          -----------------        -----------------
(State or other jurisdiction      (Commission File No.)     (IRS Employer
      of incorporation)                                      Identification No.)

                              8229 Boone Blvd. #802
                                Vienna, VA 22182
                 -----------------------------------------------
          (Address of principal executive offices, including Zip Code)

       Registrant's telephone number, including area code: (703) 506-9460


                                       N/A
                 -----------------------------------------------
          (Former name or former address if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligations of the registrant under any of the
following provisions:

[]  Written  communications  pursuant  to Rule 425  under the  Securities  Act
    (17CFR 230.425)

[]  Soliciting  material  pursuant to Rule 14a-12  under the  Exchange Act (17
    CFR 240.14a-12)

[]  Pre-commencement  communications  pursuant  to  Rule  14d-2(b)  under  the
    Exchange Act (17 CFR 240.14d-2(b)

[]  Pre-commencement  communications  pursuant  to  Rule  13e-4(c)  under  the
    Exchange Act (17 CFR 240.13e-14c))

Indicate by check mark whether the registrant is an emerging growth company as
defined in Rule 405 of the Securities Act of 1933 (ss.203.405 of this chapter)
or Rule 12b-2 of the Securities Exchange Act of 1934 (ss.204.12b-2 of this
chapter.

Emerging growth company [ ]

If an emerging  growth  company,  indicate by check mark if the  registrant  has
elected not to use the extended  transition period for complying with any new or
revised financial accounting standards provided pursuant to Section 13(a) of the
Exchange Act. [ ]

                                       1
<PAGE>


Item 1.01.  Entry Into a Material Definitive Agreement.

     On June 22, 2017 the Company sold convertible notes in the principal amount
of $1,510,000 to private investors.

     The notes bear  interest at 4% per year and are due and payable on December
22, 2017.  At the option of the note  holders,  the notes can be converted  into
shares of the Company's common stock at a conversion rate of $1.69.

     On July 24, 2017 the Company sold convertible notes in the principal amount
of $1,235,000 to private investors.

     The notes bear  interest at 4% per year and are due and payable on December
22, 2017.  At the option of the note  holders,  the notes can be converted  into
shares of the Company's common stock at a conversion rate of $2.29.

     On November 2, 2017 holders of convertible notes in the principal amount of
$1,059,300  sold in June 2017 and holders of convertible  notes in the principal
amount of  $1,235,000  sold in July 2017 agreed to extend the  maturity  date of
these notes to September 21, 2018.

     In consideration  for the extension of the maturity date of the convertible
notes,  the  Company  issued  a total  of  716,400  Series  RR  warrants  to the
convertible  note holders that agreed to the  extension.  Each Series RR warrant
entitles the holder to purchase one share of the  Company's  common  stock.  The
Series RR warrants may be exercised at any time on or before October 30, 2022 at
an exercise price of $1.65 per share.

Item 2.03.  Creation of Direct Final Obligation or an Obligation under an
            Off-Balance Sheet Arrangement of a Registrant.

     See Item 1.01 of this report.

Item 3.02.  Unregistered Sales of Equity Securities.

     The Company  relied upon the exemption  provided by Section  4(a)(2) of the
Securities Act of 1933 with respect to the issuance of the securities  described
in Item 1.01 of this report.  The persons who  acquired  these  securities  were
sophisticated  investors  and  were  provided  full  information  regarding  the
Company.  There was no general solicitation in connection with the offer or sale
of these securities. The persons who acquired these securities acquired them for
their own  accounts.  The  certificates  representing  these  securities  bear a
restricted  legend  providing  that they  cannot be sold  except  pursuant to an
effective registration statement or an exemption from registration.

                                       2
<PAGE>

                                   SIGNATURES

     Pursuant to the  requirements  of the Securities  Exchange Act of 1934, the
registrant  has duly  caused  this  report  to be  signed  on its  behalf by the
undersigned hereunto duly authorized.


Date:  November 3, 2017             CEL-SCI CORPORATION



                                    By:  /s/ Patricia B. Prichep
                                         -----------------------------------
                                         Patricia B. Prichep,
                                         Senior Vice President of Operations
[{"type": "8-K", "sequence": "1", "filename": "form8k101seriesrr11-17.txt", "description": "FORM 8-K ITEM 1.01 SERIES RR WARRANTS", "secsgml_size_bytes": 5653}]
{"company-data": {"conformed-name": "CEL SCI CORP", "cik": "0000725363", "assigned-sic": "2836", "irs-number": "840916344", "state-of-incorporation": "CO", "fiscal-year-end": "0930"}, "filing-values": {"form-type": "8-K", "act": "34", "file-number": "001-11889", "film-number": "171177505"}, "business-address": {"street1": "8229 BOONE BLVD .", "street2": "SUITE 802", "city": "VIENNA", "state": "VA", "zip": "22182", "phone": "7035069460"}, "mail-address": {"street1": "8229 BOONE BLVD.", "street2": "SUITE 802", "city": "VIENNA", "state": "VA", "zip": "22182"}, "former-company": {"former-conformed-name": "INTERLEUKIN 2 INC", "date-changed": "19880317"}}
UNITED STATES
                       SECURITIES AND EXCHANGE COMMISSION
                              Washington, DC 20549

                                    FORM 8-K

                                 CURRENT REPORT
                     Pursuant to Section 13 or 15(d) of the
                         Securities Exchange Act of 1934

       Date of Report (Date of earliest event reported): November 2, 2017

                               CEL-SCI CORPORATION
                 -----------------------------------------------
             (Exact name of registrant as specified in its charter)

          Colorado                       001-11889               84-0916344
 -------------------------          -----------------        -----------------
(State or other jurisdiction      (Commission File No.)     (IRS Employer
      of incorporation)                                      Identification No.)

                              8229 Boone Blvd. #802
                                Vienna, VA 22182
                 -----------------------------------------------
          (Address of principal executive offices, including Zip Code)

       Registrant's telephone number, including area code: (703) 506-9460

                                       N/A
                 -----------------------------------------------
          (Former name or former address if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligations of the registrant under any of the
following provisions:

[]  Written  communications  pursuant  to Rule 425  under the  Securities  Act
    (17CFR 230.425)

[]  Soliciting  material  pursuant to Rule 14a-12  under the  Exchange Act (17
    CFR 240.14a-12)

[]  Pre-commencement  communications  pursuant  to  Rule  14d-2(b)  under  the
    Exchange Act (17 CFR 240.14d-2(b)

[]  Pre-commencement  communications  pursuant  to  Rule  13e-4(c)  under  the
    Exchange Act (17 CFR 240.13e-14c))

Indicate by check mark whether the registrant is an emerging growth company as
defined in Rule 405 of the Securities Act of 1933 (ss.203.405 of this chapter)
or Rule 12b-2 of the Securities Exchange Act of 1934 (ss.204.12b-2 of this
chapter.

Emerging growth company [ ]

If an emerging  growth  company,  indicate by check mark if the  registrant  has
elected not to use the extended  transition period for complying with any new or
revised financial accounting standards provided pursuant to Section 13(a) of the
Exchange Act. [ ]

                                       1
Item 1.01.  Entry Into a Material Definitive Agreement.

     On June 22, 2017 the Company sold convertible notes in the principal amount
of $1,510,000 to private investors.

     The notes bear  interest at 4% per year and are due and payable on December
22, 2017.  At the option of the note  holders,  the notes can be converted  into
shares of the Company's common stock at a conversion rate of $1.69.

     On July 24, 2017 the Company sold convertible notes in the principal amount
of $1,235,000 to private investors.

     The notes bear  interest at 4% per year and are due and payable on December
22, 2017.  At the option of the note  holders,  the notes can be converted  into
shares of the Company's common stock at a conversion rate of $2.29.

     On November 2, 2017 holders of convertible notes in the principal amount of
$1,059,300  sold in June 2017 and holders of convertible  notes in the principal
amount of  $1,235,000  sold in July 2017 agreed to extend the  maturity  date of
these notes to September 21, 2018.

     In consideration  for the extension of the maturity date of the convertible
notes,  the  Company  issued  a total  of  716,400  Series  RR  warrants  to the
convertible  note holders that agreed to the  extension.  Each Series RR warrant
entitles the holder to purchase one share of the  Company's  common  stock.  The
Series RR warrants may be exercised at any time on or before October 30, 2022 at
an exercise price of $1.65 per share.

Item 2.03.  Creation of Direct Final Obligation or an Obligation under an
            Off-Balance Sheet Arrangement of a Registrant.

     See Item 1.01 of this report.

Item 3.02.  Unregistered Sales of Equity Securities.

     The Company  relied upon the exemption  provided by Section  4(a)(2) of the
Securities Act of 1933 with respect to the issuance of the securities  described
in Item 1.01 of this report.  The persons who  acquired  these  securities  were
sophisticated  investors  and  were  provided  full  information  regarding  the
Company.  There was no general solicitation in connection with the offer or sale
of these securities. The persons who acquired these securities acquired them for
their own  accounts.  The  certificates  representing  these  securities  bear a
restricted  legend  providing  that they  cannot be sold  except  pursuant to an
effective registration statement or an exemption from registration.

                                       2
SIGNATURES

     Pursuant to the  requirements  of the Securities  Exchange Act of 1934, the
registrant  has duly  caused  this  report  to be  signed  on its  behalf by the
undersigned hereunto duly authorized.

Date:  November 3, 2017             CEL-SCI CORPORATION

                                    By:  /s/ Patricia B. Prichep
                                         -----------------------------------
                                         Patricia B. Prichep,
                                         Senior Vice President of Operations